Dianthus Therapeutics Inc... (DNTH)
20.21
0.34 (1.69%)
At close: Jan 15, 2025, 9:48 AM
Company Description
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases.
It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
Dianthus Therapeutics Inc.
| Country | United States |
| IPO Date | Jun 21, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 53 |
| CEO | Marino Garcia M.B.A. |
Contact Details
Address: 7 Times Square New York, New York United States | |
| Website | https://dianthustx.com |
Stock Details
| Ticker Symbol | DNTH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001690585 |
| CUSIP Number | 252828108 |
| ISIN Number | US2528281080 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Marino Garcia M.B.A. | President, Chief Executive Officer & Director |
| Kristina Maximenko | Chief People Officer |
| Ryan Savitz | Chief Financial Officer & Chief Business Officer |
| Adam M. Veness Esq. | Senior Vice President, General Counsel & Secretary |
| Dr. Jeffrey Stavenhagen Ph.D. | Chief Scientific Officer |
| Edward G. Carr | Chief Accounting Officer |
| Jennifer Davis Ruff | Vice President and Head of Investor Relations & Corporate Affairs. |
| Judson Taylor | Head of Technical Operations |
| Rashieda Gluck | Head of Clinical Development Operations |
| Simrat Randhawa M.B.A., M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 12, 2024 | 8-K | Current Report |
| Dec 03, 2024 | SC 13D/A | [Amend] Filing |
| Nov 22, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 08, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 07, 2024 | 10-Q | Quarterly Report |
| Nov 07, 2024 | 8-K | Current Report |
| Oct 24, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Oct 21, 2024 | RW | Filing |